Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

“Going forward, patients and medical teams have a choice of two pathways for chest pain relief: chest pain medication or PCI," one cardiologist said. 

While its sentences varied in length, GPT-4 produced shorter radiology reports without missing the facts. 

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

Browse through some of the many highlights from TCT 2023 in San Francisco.

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

Research out of China found that the pairing proved to be more accurate in identifying cancer in nonmass-like lesions.

Researchers have shed light on the relationship between breast cancer screening and sociodemographic factors.